Print Page      Close Window     

Investors

SEC Filings

6-K
OBSEVA SA filed this Form 6-K on 03/30/2018
Entire Document
 


LOGO

 

2017 Accomplishments and 2018-19 Expected Milestones                     Milestone                 Timing     OBE2109 (Endometriosis): Completed EDELWEISS trial EU/US patient enrollment                 4Q 2017    NOLASIBAN (IVF): Completed IMPLANT2 trial recruitment                 3Q 2017    OBE022 (Preterm labor): Initiate Phase 2a PROLONG proof-of-concept clinical trial     4Q 2017    NOLASIBAN (IVF): IMPLANT2 Phase 3 primary endpoint data                 1Q 2018    OBE2109 (Endometriosis): Phase 2b EDELWEISS 12 week primary endpoint data (pain)     Mid-2018    NOLASIBAN (IVF): Live birth rate (LBR) results from IMPLANT2 trial                 4Q 2018    NOLASIBAN (IVF): Initiation of IMPLANT3 Trial in the U.S.                 4Q 2018    OBE2109 (Endometriosis): Phase 2b EDELWEISS 24 week BMD safety results                 4Q 2018    OBE2109 (Uterine Fibroids): Enrollment completion in Phase 3 PRIMROSE 1 and 2 trials 4Q 2018    OBE022 (Preterm labor): Phase 2a PROLONG interim data                 Late 2018 OBE2109 (Endometriosis): Initiation of Phase 3 Clinical Trial Program                 Late 2018/early 2019 NOLASIBAN (IVF): 6 month baby follow-up from IMPLANT2 trial                 2Q 2019    OBE2109 (Uterine Fibroids): Phase 3 PRIMROSE 1 and 2 , 24 week primary endpoint data 2H 2019    US Phase 3 IMPLANT3 primary endpoint data (Ongoing Clinical Pregnancy 10 weeks)                 4Q 2019    NOLASIBAN (IVF): Target EU MAA regulatory submission                 2H 2019